Results 61 to 70 of about 52,753 (266)
Emerging Contaminants, 2022 Efavirenz is an antiretroviral drug (ARV) used for the treatment of Human Immunodeficiency Virus (HIV/AIDS) infections. The effects efavirenz may have on mammals is known, however, little is known about the effects on non-target aquatic organisms ...
Saisha Kowlaser +2 more
doaj +1 more source
BioMed Research International, 2017 The nonnucleoside reverse transcriptase inhibitors, used for the treatment of HIV infections, are reported to have low bioavailability pertaining to high first-pass metabolism, high protein binding, and enzymatic metabolism.
Shweta Gupta +4 more
semanticscholar +1 more source
Substantial Effect of Efavirenz Monotherapy on Bilirubin Levels in Healthy Volunteers
Current Therapeutic Research, 2014 Background: Efavirenz exhibits multiple interactions with drug-metabolizing enzymes and transporters, and for this reason efavirenz-based HIV therapy is associated with altered pharmacokinetics of coadministered drugs.
Ingrid F. Metzger, PhD +10 more
doaj +1 more source
Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapy. [PDF]
PLoS ONE, 2014 OBJECTIVES: Plasma efavirenz concentrations in HIV-infected patients with tuberculosis (TB) may be affected by cytochrome P450 (CYP) 2B6 single-nucleotide polymorphisms and concurrent rifampicin use.
Kuan-Yeh Lee +9 more
doaj +1 more source
Induction of Multiple Drug Transporters by Efavirenz
Journal of Pharmacological Sciences, 2009 Efavirenz, an important component of human immunodeficiency virus 1 (HIV-1) therapy, causes substantial drug interactions as an inducer of cytochromes and the transporter ABCB1. So far its effect on the expression of other transporters is unknown.
Johanna Weiss +5 more
doaj +1 more source
Heliyon, 2021 Efavirenz is inhibitor of non-nucleoside reverse transcriptase enzyme; BCS class II drug. The objective of the present research was to prepare and evaluate nanosuspension of Efavirenz for the treatment of neuro-AIDS.
Smita Kakad, Sanjay Kshirsagar
doaj +1 more source
Chemistry – A European Journal, EarlyView.Why add another catalyst when the product itself holds the power to catalyze its own formation? Autocatalysis in synthetic chemistry enhances reaction efficiency and uncovers novel catalytic behavior across both closed‐shell and open‐shell systems, expanding reactivity and enabling innovative design strategies.
Jaspreet Kaur, Joshua P. Barham
wiley +1 more source
Pharmacokinetic interactions between rifampicin and efavirenz in HIV-TB coinfections [PDF]
Universa Medicina, 2009 The increased percentage of patients with HIV-TB coinfection leads to inevitable interactions between rifampicin and efavirenz. Efavirenz is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV infection.
Yenny
doaj
Pharmacokinetic interactions between rifampicin and efavirenz in HIV-TB coinfections
Universa Medicina, 2016 The increased percentage of patients with HIV-TB coinfection leads to inevitable interactions between rifampicin and efavirenz. Efavirenz is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV infection.
Yenny Yenny
doaj +1 more source
A Mutagenetic Tree Hidden Markov Model for Longitudinal Clonal HIV Sequence Data
, 2006 RNA viruses provide prominent examples of measurably evolving populations. In HIV infection, the development of drug resistance is of particular interest, because precise predictions of the outcome of this evolutionary process are a prerequisite for the ...
Bacheler +14 more
core +2 more sources